Search
Novartis to Acquire Regulus Therapeutics, a Biotech Firm, for Up to $1.7 Billion
2025-04-30 /
Read about 0 minute
Author：小编
Novartis has announced an agreement to acquire Regulus Therapeutics, a pioneering biotech company specializing in the development of microRNA therapies for the treatment of autosomal dominant polycystic kidney disease (ADPKD). The acquisition includes an initial payment of $800 million, with the potential for additional future payments totaling $900 million. The transaction is anticipated to conclude in the second half of this year.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
